Introduction
Patients and methods
Patients
Clinical management
Butyrylcholinesterase measurement
Statistical analysis
Results
Number (%) | Median (IQR) serum BChE levels (IU/L) | p-value | |
---|---|---|---|
Age
| 0.09a | ||
<70 years | 284 (79.8) | 6280 (5010–7860) | |
≥70 years | 72 (20.2) | 5930 (4790–7270) | |
BMI
| <0.001b | ||
Underweight | 18 (5.1) | 5970 (4210–6700) | |
Normal weight | 126 (35.4) | 5900 (4670–7030) | |
Overweight/obese | 148 (41.6) | 6780 (5540–8030) | |
NA | 64 (18) | – | |
FIGO tumor stage
| 0.04b,c | ||
IB1 | 12 (3.4) | 7500 (4790–7660) | |
IB2 | 7 (2) | ||
IIA1 | 7 (2) | 6490 (5080–7970) | |
IIA2 | 4 (1.1) | ||
IIB | 116 (32.6) | ||
IIIA | 3 (0.8) | 5960 (4810–7010) | |
IIIB | 142 (39.9) | ||
IVA | 14 (3.9) | 6520 (5080–8010) | |
IVB | 51 (14.3) | ||
Histologic subtype
| 0.1b | ||
Squamous cell carcinoma | 317 (89.0) | 6220 (5020–7750) | |
Adenocarcinoma | 32 (9) | 6200 (4870–7670) | |
Others (clear cell, serous papillary) | 7 (2) | 4790 (4160–5920) | |
Histologic grading
| 0.8b | ||
G1 | 14 (3.9) | 6010 (4510–7570) | |
G2 | 190 (53.4) | 6110 (4970–7580) | |
G3 | 122 (34.3) | 5060 (6180–7980) | |
NA | 30 (8.4) | – | |
Lymph node metastases
d
| 0.3b | ||
No | 171 (48) | 6340 (5040–7840) | |
Pelvic only | 124 (34.8) | 6000 (4950–7200) | |
Periaortic only | 5 (1.4) | 8650 (4150–9600) | |
Pelvic and periaortic | 45 (12.6) | 6570 (5610–7630) | |
NA | 11 (3.2) | – | |
Tumor size
| 0.1a | ||
<40 mm | 85 (23.9) | 6340 (5070–7650) | |
≥40 mm | 227 (63.8) | 6930 (4790–7220) | |
NA | 44 (12.3) | – | |
Response to treatment
| 0.002b | ||
Response | 336 (94.4) | 6250 (5030–7780) | |
Persistent or progressive disease | 20 (5.6) | 5050 (3660–6420) | |
Recurrence
| 0.003a | ||
Yes | 138 (38.8) | 5620 (4810–7090) | |
No | 218 (61.2) | 6400 (5070–7900) | |
Status at last observation
| <0.001b | ||
Free of disease | 173 (48.6) | 6670 (5380–8030) | |
Stable disease | 5 (1.4) | 7890 (5590–9670) | |
Progressive disease | 19 (5.3) | 6500 (5120–8420) | |
Non-cancer-related death | 54 (15.2) | 5920 (4470–7100) | |
Cancer-related death | 105 (29.5) | 5560 (4690–6930) |
Progression-free survival | Cancer-specific survival | Overall survival | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariateb | Univariate | Multivariateb | Univariate | Multivariateb | |||||||
P-valuea | HR (95% CI)b | P-value | HR (95% CI) | P-valuea | HR (95% CI)b | P-value | HR (95% CI) | P-valuea | HR (95% CI)b | P-value | HR (95% CI) | |
Log age | 0.2b | 0.6 (0.3–1.3) | – | – | 0.3b | 0.6 (0.3–1.5) | – | – | 0.002b | 2.8 (1.5–5.5) | 0.004 | 2.7 (1.3–5.4) |
BMIc | 0.9 | 0.9 (0.7–1.3) | – | – | 0.9 | 0.9 (0.6–1.4) | – | – | 0.7 | 0.9 (0.6–1.2) | – | – |
FIGO tumor staged | <0.001 | 2.2 (1.7–2.7) | <0.001 | 2.6 (1.6–3.9) | <0.001 | 2.2 (1.7–2.8) | <0.001 | 2.8 (1.7–4.7) | <0.001 | 1.6 (1.3–2.0) | <0.001 | 2.3 (1.5–3.5) |
Lymph node metastasese | 0.001 | 1.8 (1.4–2.2) | 0.1 | 0.7 (0.4–1.1) | <0.001 | 1.8 (1.4–2.3) | 0.1 | 0.7 (0.4–1.1) | <0.001 | 1.8 (1.4–2.3) | 0.04 | 0.7 (0.4–0.9) |
Gradingf | 0.7 | 0.9 (0.8–1.2) | – | – | 0.6 | 0.9 (0.7–1.2) | – | – | 0.2 | 0.9 (0.7–1.1) | – | – |
Histologic subtypeg | 0.004 | 1.9 (1.2–3) | 0.04 | 1.6 (1.1–2.6) | 0.01 | 1.9 (1.1–3.1) | 0.07 | 1.6 (0.9–2.8) | 0.2 | 1.3 (0.8–2.1) | – | – |
Log Tumor size | <0.001b | 2.7 (1.6–4.5) | 0.04 | 1.7 (1.1–2.8) | <0.001b | 3.0 (1.6–5.4) | 0.04 | 1.8 (1.1–3.3) | 0.001b | 2.2 (1.4–3.6) | 0.04 | 1.6 (1.1–2.6) |
BChEh | <0.001 | 2.1 (1.4–3.2) | 0.002 | 1.8 (1.2–2.6) | <0.001 | 2.8 (1.7–4.5) | 0.001 | 2.2 (1.4–3.5) | <0.001 | 2.1 (1.5–3.1) | <0.001 | 2.04 (1.4–2.9) |